Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Aug 07, 2018

Entered into agreement to acquire Agilis Biotherapeutics In-licensed LATAM commercial rights to Tegsedi™ (inotersen) and Waylivra™ (volanesorsen) EC approval of Translarna™ label expansion to children as young as 2 years of age Compelling data from FIREFISH study SOUTH PLAINFIELD, N.J. , Aug.

Additional Formats
Aug 02, 2018

- PTC in-licenses regional rights to TEGSEDI™ and WAYLIVRA™ from Akcea - SOUTH PLAINFIELD, N.J. and CAMBRIDGE, Mass. , Aug. 2, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), and Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc.

Additional Formats
Jul 26, 2018

SOUTH PLAINFIELD, N.J. , July 26, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2018 financial results and provide an update on the company's business and outlook on Tuesday, August 7,

Additional Formats
Jul 24, 2018

- Post hoc analysis of the placebo arm of ACT DMD Data Published in Muscle & Nerve - SOUTH PLAINFIELD, N.J. , July 24, 2018 /PRNewswire/ --   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the publication of data in Muscle & Nerve comparing the efficacy and safety of deflazacort and

Additional Formats
Jul 19, 2018

- Expands and diversifies current pipeline with four gene therapy programs - - BLA submission in AADC deficiency expected in 2019 - SOUTH PLAINFIELD, N.J. , July 19, 2018 /PRNewswire/ --   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has entered into an agreement to acquire Agilis

Additional Formats
Jul 09, 2018

SOUTH PLAINFIELD, N.J. , July 9, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced the presentation of data from the Translarna (ataluren) Phase II Study 030 demonstrating that the safety and pharmacokinetic profile of Translarna in children from two to five years with

Additional Formats
Jun 16, 2018

- risdiplam (RG7916) is well tolerated at all dose levels with no drug-related safety findings - SOUTH PLAINFIELD, N.J. , June 16, 2018 /PRNewswire/ --   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of updated interim clinical data from Part 1 of the FIREFISH study

Additional Formats
Jun 08, 2018

SOUTH PLAINFIELD, N.J. , June 8, 2018 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on June 7 , 2018 it approved non-statutory stock options to purchase an aggregate of 134,450 shares of its common stock to 18 new employees and a restricted stock unit for 3,000 shares

Additional Formats
Jun 01, 2018

- European Commission ratification anticipated in coming months - - Approval of the Translarna annual re-assessment also recommended by CHMP - SOUTH PLAINFIELD, N.J. , June 1, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Committee for Medicinal Products for

Additional Formats
May 09, 2018

SOUTH PLAINFIELD, N.J. , May 9, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending March 31, 2018 . "Over the past twenty years it has been our mission to bring clinically differentiated

Additional Formats